Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders.
Bipolar disorder
Concentration/dose ratio
Lamotrigine
Plasma level
Journal
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
27
01
2023
revised:
29
03
2023
accepted:
04
04
2023
medline:
11
3
2024
pubmed:
11
3
2024
entrez:
11
3
2024
Statut:
ppublish
Résumé
Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it. We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio. The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT - 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) - 0.588*antidepressant co-prescription (yes or no) - 0.357*gender (F = 1.899, p = 0.057, adjusted R
Identifiants
pubmed: 38465581
pii: S0924-977X(23)00073-1
doi: 10.1016/j.euroneuro.2023.04.005
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-81Informations de copyright
Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Ludovic Samalin has received CME-related honoraria and served as consultant for Janssen- Cilag, Lundbeck, Otsuka, Sanofi-Aventis with no financial or other relationship relevant to the subject of this article. Bruno Etain has served as consultant for Sanofi-Aventis with no financial or other relationship relevant to the subject of this article. Raoul Belzeaux received CME- related honoraria and served as consultant for Janssen-Cilag, Lundbeck, Sanofi-Aventis with no financial or other relationship relevant to the subject of this article. The other authors declared no conflict of interest in relation to this article.